Transplantation of neonatal porcine islets and sertoli cells into nonimmunosuppressed nonhuman primates

A Mexican group reported transplantation of cocultured neonatal porcine islets and Sertoli cells resulting in insulin independence in nonimmunosuppressed type 1 diabetes patients. We have transplanted similar islets alone (naked islets) or cocultured islets with sertoli cells (islet/sertoli cells) into an omental site and other locations of seven nondiabetic, nonimmunosuppressed, nonhuman primates. Porcine endogenous retrovirus was not detected in recipient blood 8 weeks after porcine islet grafts, and porcine C-peptide was detected at a very low level in all animals. Histology examination failed to demonstrate obviously recognizable islets, but in the animals transplanted with islet/Sertoli cells at the omentum site, there were some surviving glucagons, pan-cytokeratin, and inhibin stained cells at 8 weeks.     

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine

Highly active antiretroviral therapy has substantially improved prognosis in human immunodeficiency virus (HIV). However, the integration of proviral DNA, development of viral resistance, and lack of permeability of drugs into sanctuary sites (e.g., brain and lymphocyte) are major limitations to current regimens. Previous studies have indicated that the antimalarial drug chloroquine (CQ) has antiviral efficacy and a synergism with HIV protease inhibitors. We have screened a panel of antimalarial compounds for activity against HIV-1 in vitro. A limited efficacy was observed for CQ, mefloquine (MQ), and mepacrine (MC). However, marked synergy was observed between MQ and saquinavir (SQV), but not CQ in U937 cells. Furthermore, enhancement of the antiviral activity of SQV and four other protease inhibitors (PIs) by MQ was observed in MT4 cells, indicating a class specific rather than a drug-specific phenomenon. We demonstrate that these observations are a result of inhibition of multiple drug efflux proteins by MQ and that MQ also displaces SQV from orosomucoid in vitro. Finally, coadministration of MQ and SQV in CD-1 mice dramatically altered the tissue distribution of SQV, resulting in a >3-fold and >2-fold increase in the tissue/blood ratio for brain and testis, respectively. This pharmacological enhancement of in vitro antiviral activity of PIs by MQ now warrants further examination in vivo.     

Computer-aided detection in the United Kingdom National Breast Screening Programme: prospective study

PURPOSE: To evaluate prospectively the recall and cancer detection rates with and without computer-aided detection (CAD) in the United Kingdom National Health Service Breast Screening Programme. MATERIALS AND METHODS: The study had appropriate ethics committee approval. Informed consent was not required; however, patients were informed that their mammograms might be used in research efforts, and all patients agreed to participate. Mammograms obtained in 6111 women (mean age, 58.4 years) undergoing routine screening every 3 years were analyzed with a CAD system. Mammograms were independently double read. Twelve readers participated. Readers recorded an initial evaluation, viewed the CAD prompts, and recorded a final evaluation. Recall to assessment was decided after arbitration. Sensitivities were calculated for single reading, single reading with CAD, and double reading, as a proportion of the total number of cancers detected by using double reading with CAD. RESULTS: A total of 62 cancers were detected in 61 women. CAD prompted 51 (84%) of 61 radiographically detected cancers. Of 12 cancers missed on single reading, nine were correctly prompted; however, seven prompts were overruled by the reader. Sensitivity of single reading was 90.2% (95% confidence interval [CI]: 83.0%, 95.0%), single reading with CAD was 91.5% (95% CI: 85.0%, 96.0%), and double reading without CAD was 98.4% (95% CI: 91.0%, 100%). Cancer detection rate was 1%. Recall to assessment rate was 6.1%, with an increase of 5.8% because of CAD. Average time required, per reader, to read a case was 25 seconds without CAD and 45 seconds with CAD. CONCLUSION: CAD increases sensitivity of single reading by 1.3%, whereas double reading increases sensitivity by 8.2%.     

Phased-array magnetic resonance imaging of the prostate with correlation to radical prostatectomy specimens: local experience

PURPOSE: To evaluate local experience of phased-array magnetic resonance imaging (MRI) in the staging of locally advanced prostate carcinoma with comparison to clinical staging. METHODS: The study population was 21 patients who underwent preoperative MRI with pelvic phased-array coils followed by radical prostatectomy. The MRI findings were correlated with completely embedded serially sliced and whole-mounted sections of the prostate gland and clinical staging. RESULTS: Overall accuracy of 57.1% was obtained, with specificity of 90.0% and sensitivity of 27.3%. All but one case of locally advanced disease missed by MRI was microscopic. Clinical staging in these cases also achieved accuracy of 57.1%, specificity of 90.0% and sensitivity of 27.3%. CONCLUSIONS: MRI with a phased-array coil has high specificity but low sensitivity for detection of extraprostatic disease. Phased-array MRI does not image microscopic tumour extension. It did not perform better than clinical staging and is not recommended for routine staging.     

Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse

The hph-1 ENU-mutant mouse provides a model of tetrahydrobiopterin deficiency for studying hyperphenylalaninaemia, dopa-response dystonia, and vascular dysfunction. We have successively localized the hph-1 mutation to a congenic interval of 1.6-2.8 Mb, containing the GCH gene encoding GTP cyclohydrolase I (GTP-CH I). We used these data to establish a PCR method for genotyping wild type, hph-1 and heterozygote mice, and found that heterozygote animals have partial tetrahydrobiopterin deficiency. These new findings will extend the utility of the hph-1 mouse in studies of GTP-CH I deficiency.